News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The trial will be conducted across eight sites in Maharashtra
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Subscribe To Our Newsletter & Stay Updated
